Primary Prevention of Cardiovascular Disease (CVD)(beta)
Based on guidelines from the American College of Cardiology and the American Heart Association.
Atherosclerotic Cardiovascular Disease (ASCVD) Prevention
A team-based care approach is recommended for the control of risk factors associated with ASCVD.
For adults 40 to 75 years of age, clinicians should routinely assess traditional cardiovascular risk factors and calculate 10-year risk of ASCVD by using the pooled cohort equations (PCE).
For adults 20 to 39 years of age, it is reasonable to assess traditional ASCVD risk factors at least every 4 to 6 years.
In adults at borderline risk (5% to <7.5% 10-year ASCVD risk) or intermediate risk (≥7.5% to <20% 10-year ASCVD risk), it is reasonable to use additional risk-enhancing factors to guide decisions about preventive interventions (e.g. statin therapy).
In adults at intermediate risk (≥7.5%to <20% 10-year ASCVD risk) or selected adults at borderline risk (5% to <7.5% 10-year ASCVD risk), if risk-based decisions for preventive interventions (e.g. statin therapy) remain uncertain, it is reasonable to measure a coronary artery calcium score to guide clinician–patient risk discussion.
For adults 20 to 39 years of age and for those 40 to 59 years of age who have <7.5% 10-year ASCVD risk, estimating lifetime or 30-year ASCVD risk may be considered.
Lifestyle Factors Affecting Cardiovascular Risk
A diet emphasizing intake of vegetables, fruits, legumes, nuts, whole grains, and fish is recommended to decrease ASCVD risk factors.
Replacement of saturated fat with dietary monounsaturated and polyunsaturated fats can be beneficial to reduce ASCVD risk.
A diet containing reduced amounts of cholesterol and sodium can be beneficial to decrease ASCVD risk.
As a part of a healthy diet, it is reasonable to minimize the intake of processed meats, refined carbohydrates, and sweetened beverages to reduce ASCVD risk.
Adults should be routinely counseled in healthcare visits to optimize a physically active lifestyle.
Adults should engage in at least 150 minutes per week of accumulated moderate-intensity or 75 minutes per week of vigorous-intensity aerobic physical activity (or an equivalent combination of moderate and vigorous activity) to reduce ASCVD risk.
For adults unable to meet the minimum physical activity recommendations (at least 150 minutes per week of accumulated moderate-intensity or 75 minutes per week of vigorous-intensity aerobic physical activity), engaging in some moderate- or vigorous-intensity physical activity, even if less than this recommended amount, can be beneficial to reduce ASCVD risk.
Other Factors Affecting Cardiovascular Risk
In individuals with overweight and obesity, weight loss is recommended to improve the ASCVD risk factor profile.
Counseling and comprehensive lifestyle interventions, including calorie restriction, are recommended for achieving and maintaining weight loss in adults with overweight and obesity.
Calculating body mass index (BMI) is recommended annually or more frequently to identify adults with overweight and obesity for weight loss considerations.
For all adults with T2DM, a tailored nutrition plan focusing on a heart healthy dietary pattern is recommended to improve glycemic control, achieve weight loss if needed, and improve other ASCVD risk factors.
Adults with T2DM should perform at least 150 minutes per week of moderate-intensity physical activity or 75 minutes of vigorous-intensity physical activity to improve glycemic control, achieve weight loss if needed, and improve other ASCVD risk factors.
For adults with T2DM, it is reasonable to initiate metformin as first-line therapy along with lifestyle therapies at the time of diagnosis to improve glycemic control and reduce ASCVD risk.
For adults with T2DM and additional ASCVD risk factors who require glucose lowering therapy despite initial lifestyle modifications and metformin, it may be reasonable to initiate a sodium-glucose cotransporter 2 (SGLT-2) inhibitor or a glucagon-like peptide-1 receptor (GLP-1R) agonist to improve glycemic control and reduce CVD risk.
In adults at intermediate risk (≥7.5% to <20% 10-year ASCVD risk), statin therapy reduces risk of ASCVD, and in the context of a risk discussion, if a decision is made for statin therapy, a moderate-intensity statin should be recommended.
In intermediate risk (≥7.5% to <20% 10-year ASCVD risk) patients, LDL-C levels should be reduced by 30% or more, and for optimal ASCVD risk reduction, especially in patients at high risk (≥20% 10-year ASCVD risk), levels should be reduced by 50% or more.
In adults 40 to 75 years of age with diabetes, regardless of estimated 10-year ASCVD risk, moderate-intensity statin therapy is indicated.
In patients 20 to 75 years of age with an LDL-C level of 190 mg/dL (≥4.9 mmol/L) or higher, maximally tolerated statin therapy is recommended.
In adults with diabetes mellitus who have multiple ASCVD risk factors, it is reasonable to prescribe high-intensity statin therapy with the aim to reduce LDL-C levels by 50% or more.
In intermediate-risk (≥7.5% to <20% 10-year ASCVD risk) adults, risk-enhancing factors favor initiation or intensification of statin therapy.
In intermediate-risk (≥7.5% to <20% 10-year ASCVD risk) adults or selected borderline-risk (5% to <7.5% 10-year ASCVD risk) adults in whom a coronary artery calcium score is measured for the purpose of making a treatment decision, AND if the coronary artery calcium score is zero, it is reasonable to withhold statin therapy and reassess in 5 to 10 years, as long as higher-risk conditions are absent (e.g. diabetes, family history of premature CHD, cigarette smoking); if coronary artery calcium score is 1 to 99, it is reasonable to initiate statin therapy for patients ≥55 years of age; if coronary artery calcium score is 100 or higher or in the 75th percentile or higher, it is reasonable to initiate statin therapy.
In patients at borderline risk (5% to <7.5% 10-year ASCVD risk), in risk discussion, the presence of risk-enhancing factors may justify initiation of moderate-intensity statin therapy.
In adults with elevated BP or hypertension, including those requiring antihypertensive medications nonpharmacological interventions are recommended to reduce BP. These include: weight loss; a heart-healthy dietary pattern; sodium reduction; dietary potassium supplementation; increased physical activity with a structured exercise program; and limited alcohol.
In adults with an estimated 10-year ASCVD risk of 10% or higher and an average systolic BP of 130 mmHg or higher (Level A) or an average diastolic BP of 80 mmHg or higher (Level C-EO), use of BP-lowering medications is recommended for primary prevention of CVD.
In adults with confirmed hypertension and a 10-year ASCVD event risk of 10% or higher, a BP target of less than 130/80 mmHg is recommended (Systolic BP: Level B-R; Diastolic BP: Level C-EO).
In adults with hypertension and chronic kidney disease, treatment to a BP goal of less than 130/80 mmHg is recommended (Systolic BP: Level B-R; Diastolic BP: Level C-EO).
In adults with T2DM and hypertension, antihypertensive drug treatment should be initiated at a BP of 130/80 mmHg or higher, with a treatment goal of less than 130/80 mmHg (Systolic BP: Level B-R; Diastolic BP: Level C-EO).
In adults with an estimated 10-year ASCVD risk <10% and an systolic BP of 140 mmHg or higher or a diastolic BP of 90 mmHg or higher, initiation and use of BP-lowering medication are recommended.
All adults should be assessed at every healthcare visit for tobacco use and their tobacco use status recorded as a vital sign to facilitate tobacco cessation.
In adults who use tobacco, a combination of behavioral interventions plus pharmacotherapy is recommended to maximize quit rates.
To facilitate tobacco cessation, it is reasonable to dedicate trained staff to tobacco treatment in every healthcare system.
Low-dose aspirin (75-100 mg orally daily) might be considered for the primary prevention of ASCVD among select adults 40 to 70 years of age who are at higher ASCVD risk but not at increased bleeding risk.
Low-dose aspirin (75-100 mg orally daily) should not be administered on a routine basis for the primary prevention of ASCVD among adults >70 years of age.
How strong is the ACC/AHA's recommendation?
Refer to recommendation